Innate Pharma to join bladder cancer panel at BTIG conference

Innate Pharma SA announced on July 23, 2026 that Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma, will take part in a panel discussion on the changing treatment landscape in bladder cancer at the BTIG Virtual Biotechnology Conference.¹

The session is scheduled for July 28, 2026 at 10:30 a.m. EDT, or 4:30 p.m. CEST.¹

Innate Pharma describes itself as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients.¹ The company says it focuses on antibody-engineering and target identification to develop next generation antibody therapeutics.¹

Its pipeline includes three named programs: an ADC called IPH4502 targeting Nectin-4 for solid tumors, lacutamab, an antibody against KIR3DL2 being studied in cutaneous T cell lymphomas, and monalizumab, an antibody against NKG2A being developed with AstraZeneca for non-small cell lung cancer, according to the release (Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer (NSCLC).¹)

The company also noted partnerships with other drugmakers and research groups, naming Sanofi and AstraZeneca among its collaborators in cancer immunotherapy research (Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.¹)

The company is headquartered in Marseille, France, with a US office in Rockville, MD, and its shares trade on Euronext Paris and Nasdaq.¹